ObjectiveTo explore the clinical effects of insulin aspart 30 combined with vildagliptin in the treatment of type 2 diabetes mellitus (T2DM) patients with poor glycemic control of metformin. MethodsA total of 102 T2DM patients with poor glycemic control of metformin who were diagnosed and treated in our hospital from January 2019 to May 2020 were selected as the research objects, and they were divided into study group (52 cases) and control group (50 cases) by the random number method. Patients in the control group were treated with insulin aspart 30, while patients in the study group were treated with insulin aspart 30 combined with vildagliptin, for a 3-month treatment course. The levels of fasting blood glucose (FBG), 2 hours postprandial blood glucose (2hPG) and glycosylated hemoglobin (HbA1c) were detected and compared between the two groups before and after treatment. The islet function, renal function, the average daily dosage of insulin and incidence of hypoglycemia were compared between the two groups. ResultsThe levels of FBG, 2hPG and HbA1c, fasting insulin (FINS), insulin resistance (HOMA-IR), blood uric acid (UA), serum creatinine (SCr) and the average daily dosage of insulin in the study group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). Islet β cell function (HOMA-β) in the study group was significantly better than that in the control group, with a statistically significant difference (P＜0.05). The incidence of hypoglycemia was low in both groups without statistically significant difference (P＞0.05). ConclusionThe clinical effects of insulin aspart 30 combined with vildagliptin in the treatment of type 2 diabetes mellitus patients with poor glycemic control of metformin are remarkable, with effective control of blood glucose levels, reduction of insulin dosage, improvement of islet function and kidney function in patients, and the low incidence of hypoglycemia in patients, which is worthy of popularization and application.

无